

---

## **SeneXta Therapeutics SA announces FDA approval of Investigational New Drug (IND) for SNX-001**

**Lugano, Switzerland, July 17th 2009** – SeneXta today announced that on July 14th, 2009, it has received FDA approval of its Investigational New Drug (IND) application for SNX-001, which is developed for the treatment of Alzheimer’s Disease (AD). SeneXta expects clinical dosing to begin in September 2009.

Enrico Braglia, Chief Executive Officer of SeneXta, commented: “We are delighted that the FDA has accepted our SNX-001 data package to allow us to begin a Phase I clinical trial. In less than ten months since we committed to this project, we have completed manufacturing, nonclinical toxicology, clinical design and we are ready to start new clinical testing. Reaching this important milestone demonstrates our ability to advance the development of our products quickly and efficiently, which is a key component of our business strategy”.

SeneXta will conduct a Phase I single and multiple dose escalation clinical trial in Germany. The trial has already been approved by the Hamburg Ethical Committee on June 15, 2009. Importantly, the Phase I dosing is designed to reach the previously observed therapeutic dose in AD patients. Results from this trial will be supportive for a second randomized, double-blind, placebo controlled Phase II trial already under design.

“This milestone is very important and paves the way towards an improved treatment for the patients in the USA and Europe suffering from this devastating disease,” says Dr. Moss, SNX-001 inventor.

### **About SNX-001**

SNX-001 is a selective and novel inhibitor of acetylcholinesterase (AChE) for the treatment of Alzheimer’s disease. The basic science of SNX-001-induced AChE inhibition is fundamentally different from that of the short-acting AChE inhibitors that are currently available for the treatment of Alzheimer’s. SNX-001 produces long-acting AChE inhibition, which improves its brain selectivity and reduces the peripheral toxicity (nausea, vomiting, and diarrhea) that limits the utility of short acting inhibitors. SNX-001 has been previously tested in a non-GLP study in Alzheimer’s patients with promising results.

### **About SeneXta Therapeutics SA**

SeneXta is a Swiss biopharmaceutical company engaged in the research and development of therapies for neurodegenerative disorders including Alzheimer’s disease, cognitive impairment secondary to ischemia, and other central nervous system (CNS) disorders.

SeneXta was founded to acquire intellectual properties for the treatment of CNS disorders. The Company has already recruited a world-leading team of CNS experts and established solid collaborations with U.S. and European Union universities.

For more information:

### **SENEXTA THERAPEUTICS SA**

Via Cantonale 1  
6900 Lugano  
[Switzerland](http://www.senexta.com)

[info@senexta.com](mailto:info@senexta.com)